Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

240 - Self-questionnaire to assess patient’s preferences for participation in phase I clinical trials


05 Mar 2018


Poster display


Benjamin Verret


Annals of Oncology (2018) 29 (suppl_3): iii10-iii34. 10.1093/annonc/mdy047


B. Verret1, A. Perret2, S. Delaloge2, B. Besse2, A. Le Cesne2, A. Hollebecque1, C. Baldini1, C. Massard1, J. Soria1, S. Postel-Vinay1

Author affiliations

  • 1 Drug Development Unit (ditep), Institut Gustave Roussy, 94800 - Villejuif/FR
  • 2 Department Of Cancer Medicine, Institut Gustave Roussy, 94800 - Villejuif/FR


Abstract 240

Patient Preference Assessment Tool (PPAT) is a patient self-assessment questionnaire designed by Emory (US) to allow easy and rapid evaluation of patient preferences for phase 1 (P1) trial participation. Beyond being a legal requirement, informed consent has a critical role to ensure that patient’s trial participation trial matches his/her expectations and understanding of treatment options. This tool has not been independently validated yet. We therefore aimed at assessing PPAT in two cohorts of P1 and phase 2-3 (P2-3) patients (pts) treated at Gustave Roussy (France).

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings